Literature DB >> 8731926

Effects of warm blood cardioplegic solution on myocardial protection.

X L Du1, H J Lan, Z Q Sun.   

Abstract

To evaluate the effects of warm blood cardioplegic solution on myocardial protection, normothermic induction and terminal perfusion of oxygenated blood cardioplegia in combination with intermittent administration of cold blood cardioplegia during ischemia were studied in an isolated working rat heart model. The experimental protocol consisted of a 120 min cardioplegic arrest followed by 45 min normothermic reperfusion. Myocardial content of adenosine triphosphate (ATP), recovery of the left ventricular function, release of creatine phosphokinase (CPK) and ultrastructure of myocardium were assessed before and after ischemia. The results showed that the hearts preserved with warm blood cardioplegic induction and terminal perfusion had significantly higher levels of ATP, better recovery of cardiac function and lower releases and lower releases of CPK than those receiving cold blood cardioplegia alone, with myocardial tissue being of generally normal structure. These findings suggest that warm induction and terminal perfusion of blood cardioplegic solution can accelerate myocardial metabolic and functional recovery, preserve high-energy phosphate, reduce myocardial injury and enhance myocardial protection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8731926     DOI: 10.1007/BF02887947

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  13 in total

1.  Primary cause of unsuccessful liver and heart preservation: cold sensitivity of the ATPase system.

Authors:  D R Martin; D F Scott; G L Downes; F O Belzer
Journal:  Ann Surg       Date:  1972-01       Impact factor: 12.969

2.  Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia.

Authors:  K H Teoh; G T Christakis; R D Weisel; S E Fremes; D A Mickle; A D Romaschin; R S Harding; J Ivanov; M M Madonik; I M Ross
Journal:  J Thorac Cardiovasc Surg       Date:  1986-06       Impact factor: 5.209

3.  Nucleotide degradation and functional impairment during cardioplegia: amelioration by inosine.

Authors:  D F DeWitt; K E Jochim; D M Behrendt
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

4.  Maximal oxygenation of dilute blood cardioplegic solution.

Authors:  W G Hendren; D D O'Keefe; G A Geffin; A G Denenberg; T R Love; W M Daggett
Journal:  Ann Thorac Surg       Date:  1987-07       Impact factor: 4.330

5.  Reperfusion injury in ischemic myocardium: protective effect of controlled reperfusion.

Authors:  R E Mrak; M M Carry; M L Murphy; C F Peng; K D Straub
Journal:  Am J Cardiovasc Pathol       Date:  1990

6.  Reducing postischemic damage by temporary modification of reperfusate calcium, potassium, pH, and osmolarity.

Authors:  D M Follette; K Fey; G D Buckberg; J J Helly; D L Steed; R P Foglia; J V Maloney
Journal:  J Thorac Cardiovasc Surg       Date:  1981-08       Impact factor: 5.209

7.  Reversal of ischemic damage with secondary blood cardioplegia.

Authors:  H L Lazar; G D Buckberg; A J Manganaro; R P Foglia; H Becker; D G Mulder; J V Maloney
Journal:  J Thorac Cardiovasc Surg       Date:  1979-11       Impact factor: 5.209

8.  Prevention of reperfusional damage from ischemic myocardium.

Authors:  R L Kao; G J Magovern
Journal:  J Thorac Cardiovasc Surg       Date:  1986-01       Impact factor: 5.209

9.  Failure of blood cardioplegia to protect myocardium at lower temperatures.

Authors:  G J Magovern; J T Flaherty; V L Gott; B H Bulkley; T J Gardner
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

10.  Studies of controlled reperfusion after ischemia. XXI. Reperfusate composition: superiority of blood cardioplegia over crystalloid cardioplegia in limiting reperfusion damage--importance of endogenous oxygen free radical scavengers in red blood cells.

Authors:  P L Julia; G D Buckberg; C Acar; M T Partington; M P Sherman
Journal:  J Thorac Cardiovasc Surg       Date:  1991-02       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.